WebJun 22, 2024 · Meanwhile, Guardant highlighted data that it argued has demonstrated that Foundation's offerings are actually less sensitive and specific than Guardant360. For example, the company said that Guardant360 showed 85 percent clinical sensitivity in a recent study, while tissue tests from Foundation reached only 62 percent, primarily due … WebMay 28, 2024 · However, higher cell-free DNA tumor fractions were observed in the symptomatic cohort. Sensitivity for detection of right-sided and left-sided CRC was similar (93% vs. 90%; p=0.5; Table). Conclusions: In this large early-stage CRC cohort, multimodal ctDNA assessment has high sensitivity for CRC detection with high specificity. …
Guardant Health Confident in New CRC Screening Blood Test
WebOct 26, 2024 · Precision oncology company Guardant Health announced that its LUNAR-2 blood test has demonstrated its ability to precisely detect early-stage colorectal cancer (CRC) in a study. Developed to screen average-risk patients for CRC, the blood test is said to provide enhanced sensitivity and specificity in detecting people with early-stage CRC. WebNov 11, 2024 · The primary objective of the study is to evaluate the sensitivity and specificity of a blood-based GuardantLUNAR-2 test to detect high frequency cancer in screen … currys opening times gloucester
Guardant Health collaborates with The Ohio State University ...
WebMay 7, 2024 · NEW YORK – Newly published data have provided a glimpse at the performance of Guardant Health's noninvasive and tissue-agnostic test, Guardant Reveal, for minimal residual disease detection in colorectal cancer patients.The results, though limited, suggest the assay has sensitivity and specificity comparable to competitive … WebAug 6, 2024 · Across the entire cohort, the accuracy of tissue-NGS was 96% and the sensitivity was 94.9%, while plasma-NGS had an accuracy of 63% and a sensitivity of only 52.6% ( p < 0.001 for both... WebMay 21, 2024 · At 90% specificity, the blood assay (Guardant Health) was 100% sensitive for detecting CRC. At 95% specificity, sensitivity was 88%. The blood assay detects circulating tumor DNA from cancer... charter trustees regulations